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OBJECTIVES: To estimate the budget impact of adding omalizumab to standard 
therapy (ST) in patients with uncontrolled severe allergic asthma, from the 
perspective of the Brazilian private health care system, over a 5-year time 
horizon. METHODS: A budget impact model was developed to calculate the 
budget impact for Brazil, based on local epidemiological and drug cost data. The 
eligible population was based on the following inputs: 2013 population estimate 
(age ≥6 years): 183 million; prevalence of asthma: 10%; proportion of patients 
diagnosed and receiving treatment: 6.5%; percentage with allergic asthma: 69%; 
percentage with immunoglobulin E (IgE) ≥30 IU/mL: 78.7%; percentage with 
uncontrolled, severe disease: 2.4%; proportion of population using the private 
health care system and medications: 25.1%. For the following years, an annual 
population growth rate of 1.17% was assumed. Average doses, resource 
utilization per exacerbation and proportion of patients who respond to 
omalizumab were obtained from the INNOVATE trial. Direct costs, including 
omalizumab purchase and the costs of health care consumption related to 
exacerbations and routine visits. These costs were calculated from the 
perspective of the private health care payer. Omalizumab uptake was assumed 
to be 17%, 35%, 55%, 75% and 95% of eligible population for years 1 to 5, 
respectively. RESULTS: The number of patients eligible for add-on omalizumab 
therapy that met the eligibility criteria was estimated to be around 3,887 in the 
first year. The annual budget impact of omalizumab was approximately BRL25 
million, BRL50 million, BRL77 million, BRL104 million and BRL131 million for 
years 1 to 5, respectively (BRL1=USD0.492). CONCLUSIONS: The budget impact 
for the private health care system in Brazil of adding omalizumab to ST was 
approximately BRL131 million at the end of year-5. Considering that the total 
population using the private health care system in Brazil is around 45.4 million, 
this represents a relatively small impact on the payer’s budget, of BRL2.90 per 
beneficiary.  
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OBJECTIVES: The prevalence of COPD in Brazil is estimated in 15,8% and it is the 
fourth cause of hospitalization a in the Brazilian public health system (SUS) in 
the last 10 years. Until recently only the short-action and long-action β2-agonists 
were distributed to COPD patients by SUS. The aim of this study was to 
determine the expected consequences on the cost and effectiveness and the 
budgetary impact of the recent introduction in SUS of budesonide and 
beclomethasone for the treatment of COPD patients. METHODS: Systematic 
review of the literature and development of a decision analytic model to 
demonstrate the immediate response to treatment with inhaled steroids and 
project the results in terms of effectiveness and cost based on current knowledge 
of the natural history of the disease. The analysis was performed for a 
hypothetical cohort of adults with forty or more years with COPD GOLD stage II, 
III or IV. The primary perspective of the study was SUS. Data sources were the 
medical literature, official published prices of SUS for medicines and DATASUS 
(SUS database). RESULTS: Corroborating the results of other systematic reviews 
we also did not detect differences in efficacy and safety between budesonide and 
beclomethasone therefore we performed a cost-minimization analysis. Both 
steroids reduced the exacerbation rate in about 40%. The annual costs of the 
treatment with budesonide and beclomethasone were 714,29 and 786,77, 
respectively. The parameter that led to greater variation in the model was the 
cost of hospitalizations with ICU stays. The projected budget impact for 
introduction of inhaled corticoids (50%/50%) for COPD treatment in 2013 is about 
R$345 million reais. CONCLUSIONS: There are no differences in efficacy and 
safety between the studied inhaled steroids. To achieve about 40% reduction in 
the exacerbation rate the budget impact for SUS in 2013 would be of 
approximately R$345 million reais.  
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OBJECTIVES: To evaluate the clinical and economic burden of chronic 
obstructive pulmonary disease (COPD) in the U.S. veteran population. METHODS: 
Patients diagnosed with COPD (International Classification of Disease 9thRevision 
Clinical Modification [ICD-9-CM] diagnosis codes 490.xx, 491.xx, 492.xx, 494.xx, 
495.xx, 496.xx) were included in this retrospective study (October 1, 2005 - May 
31, 2012) conducted using the Veterans Health Administration (VHA) Medical 
SAS Datasets. Health care resource utilization and costs were assessed for the 
12-month follow-up period. Patients' clinical and discharge statuses were 
examined for the 12-month baseline period. Means and standard deviations 
were provided for continuous variables. Numbers and percentage were provided 
for categorical variables. All descriptive statistical analyses were performed 
using SAS v9.3 software. RESULTS: Among all study patients diagnosed with 
COPD (772,898), major comorbidities during the baseline period included 
hypertension (27.9%), depressive disorder (6.72%), chronic ischemic heart disease 
(5.18%) and shortness of breath (4.73%). The most common medications 
prescribed within 60 days of disease identification were simvastatin (27.45%), 
lisinopril (20.63%), omeprazole (19.47%) and aspirin (12.19%). In the 12-month 
follow-up period, 49.61% of patients were prescribed short-acting b-agonists 
(SABAs) while only 60 patients were prescribed long-acting b-agonists (LABAs). 
Outpatient visits (99.75%) occurred more frequently than inpatient visits 
(22.28%). Inpatient ($8,420), outpatient ($8,584) and pharmacy costs ($1,746) 
combined for a total expenditure of $18,750. CONCLUSIONS: Patients were 
prescribed simvastatin, lisinopril and omeprazole more often within 3 months 
after disease identification than other medications. Within 1-year post-
diagnosis, SABAs were prescribed more often than LABAs as a treatment for 
COPD.  
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OBJECTIVES: Health care cost data for pulmonary arterial hypertension (PAH) are 
scarce, especially for important morbidity events like hospitalizations, owing to 
the absence of a unique ICD-9-CM code. This study assessed inpatient costs and 
length of stay (LOS) among US patients with PAH. METHODS: A retrospective 
analysis was performed using data (January 2007–December 2011) from adult 
enrollees with Commercial or Medicare Advantage with prescription drug 
coverage from a large health plan. PAH patients were identified based on both ≥1 
medical claim with an ICD-9-CM code for primary pulmonary hypertension (PH) 
(416.0) or other chronic pulmonary heart disease (416.8), and ≥1 pharmacy claim 
for a medication indicated for PAH or frequently used in PAH. Patients had to 
have ≥365 days of enrollment prior to index date (study inclusion) and 180 days 
during follow-up. Discharge diagnoses being unavailable, the principal diagnosis 
for each hospitalization was defined as the most frequent primary diagnosis on 
that hospitalization's facility claims. Total hospitalization costs (inflated to 2011 
USD using the CPI-U) and LOS, stratified by payer (excluding dual eligibility) and 
principal diagnosis, were analyzed with descriptive statistics. RESULTS: The 4009 
PAH patients (52% female, mean±SD age 60±14 years) incurred 5582 
hospitalizations. Hospitalization cost was $34,123±107,005 (mean±SD), and was 
nearly 3 times higher for hospitalizations with Commercial ($46,118±135,137, 
n=3322) than Medicare Advantage coverage ($16,319±30,046, n=2244). Average 
cost was higher for hospitalizations with a principal diagnosis of PH (416.0 or 
418.6) than other principal diagnoses ($49,722±181,878, n=878 vs $31,211± 85,821, 
n=4704). Average LOS was 11.7±20.8 days, and was longer for hospitalizations 
with Medicare than Commercial coverage (12.8±21.2 vs 10.9±20.4 days), and for 
hospitalizations with PH as principal diagnosis compared with other principal 
diagnoses (15.0±30.5 vs 11.1±18.3 days). CONCLUSIONS: Long durations and high 
incurred costs for PH-related hospitalizations reveal the severe morbidity, health 
care, and patient burden of PAH.  
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OBJECTIVES: Severe, poorly-controlled asthma affects a minority of asthma 
patients but accounts for a disproportionately large amount of asthma-related 
medical expenditures. Based on 2007 NIH (NHLBI EPR-3) guidelines, oral 
corticosteroids (OCS) are recommended therapy for step 6 management of severe 
persistent asthma. We sought to better understand asthma-related health care 
utilization in patients who require frequent OCS. METHODS: We examined 
Thomson Reuters MarketScan claims data (2006-2010) to identify patients aged 
≥12 years, continuously enrolled for ≥24 months, with OCS-dependent asthma, 
defined as ≥3 30-day OCS fills over a 12-month period and a primary asthma 
diagnosis (ICD-9 493) within 12 months of the first OCS fill. Excluded were 
patients with COPD including emphysema, cystic fibrosis, acute respiratory 
failure, and 29 other conditions that may require frequent OCS. Asthma-related 
health care utilization was examined during the 12-month period following 
patients’ first OCS fill. RESULTS: Among the 10,319 patients meeting study 
criteria, 6,941 (67.3%) were female; the mean (SD) age at first OCS fill was 57.9 
(15.9). The most common comorbid diagnoses were allergic rhinitis (n=1,507; 
14.6%), chronic sinusitis (n=1,236; 12.0%), pneumonia (n=1,066; 10.4%), and 
gastroesophageal reflux disease (n=1,036; 10.0%). During 12-month follow-up, 
patients received a mean (SD) of 6.2 (3.6) OCS fills. OCS was used in conjunction 
with at least 2 additional asthma medications in 6,671 (64.6%) patients, but only 
5,428 (52.6%) received concomitant guideline-recommended treatment with both 
an inhaled corticosteroid and long-acting beta agonist. Asthma-related 
hospitalizations and emergency department (ED) visits were experienced by 6.5% 
(n=673) and 6.9% (n=712) of patients, respectively. The mean (SD) number of 
asthma-related hospitalizations was 1.4 (1.5), with an average stay of 4.6 days; 
the mean (SD) number of asthma-related ED visits was 1.2 (0.5). CONCLUSIONS: 
Despite frequent use of OCS and additional asthma medications, this population 
of patients with asthma experienced high levels of asthma-related 
hospitalizations and ED visits.  
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OBJECTIVES: Chronic obstructive pulmonary disease is a very important problem 
for health systems of different countries trough out the world. For Ukraine as for 
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developing country, the human capital (employed economically active 
population) is the most important national asset. According to official 
epidemiological data from National center of Medical Statistics, prevalence of 
COPD in Ukraine is near 1%. According to opinions of Ukrainian leading 
pulmonologists, COPD in Ukraine is underdiagnosed and its prevalence rate 
could amount 6%. METHODS: Based on data from Ukrainian state statistics 
committee about number of employed economically active population in 2012 
we assessed the economic burden from COPD in two scenarios: “objective” – 
official disease prevalence rate 1%. We conducted by expert opinion of 35 leading 
pulmonologists and determined the real prevalence rate 6%. Our data about 
COPD costs per 1 employed economically active subject we received from our 
2012-2020 prospective model (Tolubaiev V., Zalis’ka O. et al. 2012).The 
calculations were discounted by social tax (18.6%) and Value Added Tax (17%). 
Exchange rate: 1USD=7.99UAH on 10.01.2013. RESULTS: According to the these 
research, number of employed economically active population in Ukraine could 
amount 20.393.267 in 2012. Number of employed economically active COPD 
patients in 2012 could be 203.933 and 1.223.596, according to “objective” and 
“real” prevalence scenarios, respectively. We estimated that in 2012 direct COPD 
costs could amount US$412.554.786 and US$2.475.328.717, indirect costs could 
amount US$244.735.489 and US$1.468.412.934, according to “objective” and “real” 
prevalence scenarios, respectively. CONCLUSIONS: Results show that value of 
COPD economic burden could enlarge with improvements in diagnostics of 
disease in Ukraine.  
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BACKGROUND: Allergies are among the most common chronic conditions. About 
two thirds of the population have experienced allergic symptoms in their lives. 
In the U.S., the prevalence rate is estimated to be as high as 15%, representing 40 
to 50 million individuals. Over half of the U.S. population has tested positive for 
one or more allergens. OBJECTIVES: The objective of this study was to determine 
the utilization and expenditure trends for anti-allergic agents in the U.S. 
Medicaid program. METHODS: A retrospective, descriptive analysis was 
conducted. We extracted the utilization and expenditure data from the national 
Medicaid pharmacy files, which cover 1991 first quarter to 2011 second quarter. 
The study drugs included first-generation antihistamines (e.g. 
brompheneramine, chlorpheniramine, doxylamine, and pheniramine) and 
second-generation antihistamines (e.g. azelastine, cetirizine, desloratadine, 
levocertizine, and loratadine). The quarterly prescription numbers and 
reimbursement amounts were calculated over time by summing data for 
individual drug products. The quarterly per-prescription reimbursement as a 
proxy for drug price was computed for each study drug. RESULTS: The total 
number of prescriptions for anti-allergic drugs reached a peak of 18.7 million in 
2003. The prescriptions for first-generation antihistamines dominated the 
market from 1991 to 1998, while the prescription market share for second-
generation antihistamines increased from 12.84% in 1991 first quarter to 57.17% 
in 2011 second quarter. From 1991 to 2002, the total annual Medicaid 
expenditures for antihistamines grew from $87.7 million to $757.2 million, a 
rapid increase. The average annual per-prescription price of first-generation 
antihistamines fluctuated between $8 and $17, while the per-prescription price 
of second-generation antihistamines increased from $13 to $64 from 1991 to 
2011. CONCLUSIONS: Although the U.S. Medicaid Program encourages switching 
to over-the-counter medications when available, which may be outside of the 
study’s database, utilization of and expenditures on anti-allergic medications 
have nevertheless risen substantially over the last two decades.  
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is the most common 
nosocomial infection in the intensive care unit (ICU). It’s associated with 
significant morbidity, increasing the ICU and hospital length of stay (LOS), and 
raising overall costs. Literature suggests that costs could be reduced using the 
most efficient empiric therapy. The aim of this study was to assess the cost-
effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy 
for VAP patients, from the health care payer’s perspective. METHODS: A 
decision-tree model was used to compare costs and effectiveness of linezolid 
(600 mg/12 hours) and vancomycin (1g/12 hours) (comparator) for a cohort of 
patients with VAP. Effectiveness measures were: microbiological success rates, 
mortality rates, ICU and ward LOS and overall costs. Effectiveness and 
epidemiologic data were collected from published literature. Local costs (2012 
US$) were obtained from Honduras´ Ministry of Health official databases (11). 
The model used a 12-week time horizon and only direct medical costs were 
considered (hospital LOS, medication costs, hematologic, gastrointestinal and 
skin adverse events and lab exams). Monte Carlo probabilistic sensitivity 
analysis (PSA) was constructed. RESULTS: Results showed linezolid as more 
effective and less expensive option for VAP. Clinical success rate was higher with 
linezolid (64.4%) against vancomicyn, (56.1%). Mortality was lower with linezolid 
(10.13% vs 15.74%). Average ICU (and ward) LOS was 18 (9) days with linezolid 
and 22 (10) days with vancomycin. Overall medical costs per patient were 
$22,825.45 with linezolid and $26,227.26 with vancomycin. CE analyses showed 
linezolid is the dominant strategy. Acceptability curves showed that linezolid 
would be cost-effective within <3 GDP per capita threshold. PSA outcomes 
support the robustness of these findings. CONCLUSIONS: This is the first CE 
study for VAP developed in Honduras. Linezolid resulted as the cost-saving 
option for treating VAP patients in the Honduran clinical environment.  
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OBJECTIVES: To determine the cost-effectiveness of adding omalizumab to 
standard therapy (ST) in patients with uncontrolled severe allergic asthma, from 
the perspective of the Brazilian private health care system. METHODS: The cost-
effectiveness analysis was based on Markov modeling, and estimated the costs 
and clinical outcomes, in a lifetime horizon, associated with ST with and without 
omalizumab add-on therapy. Clinical outcomes were expressed as clinically 
significant exacerbations (CSE) and clinically significant severe exacerbations 
(CSSE), according to the results of the phase III INNOVATE trial. Average doses, 
resource utilization per exacerbation, and omalizumab response rates were also 
obtained from the INNOVATE trial. Only direct costs were considered, including 
the acquisition costs of omalizumab and the costs of health care consumption 
related to exacerbations and routine visits. These costs were calculated from the 
perspective of the private health care payer. In the model, subjects transitioned 
between daily symptoms (optimized asthma control) and CSE or CSSE states, 
reflecting the clinical course of severe asthma. Patients could have several 
sequential CSE, or could remain exacerbation-free for prolonged periods, as 
determined by transition probabilities. Death states were separated into death 
from all causes, and death due to severe asthma exacerbation. One-way 
sensitivity-analysis (OWSA) was performed to assess model robustness. Costs 
and clinical outcomes were yearly discounted at 5%. RESULTS: The base-case 
analysis showed that in comparison with ST alone, the use of omalizumab+ST 
resulted in less exacerbations per patient (17.57 CSE and 9.27 CSSE avoided) at an 
additional cost of BRL163,190 (BRL1=USD0.492). Therefore, omalizumab ICERs 
were BRL9,289/CSE avoided and BRL17,597/CSSE avoided. OWSA confirmed the 
favorable results of the base-case for omalizumab. CONCLUSIONS: Considering 
the parameters applied, from the Brazilian private health care system 
perspective, omalizumab add-on therapy is very cost effective compared with ST 
alone in the treatment of patients with uncontrolled severe allergic asthma, 
costing less than the WHO threshold of 1GDP per capita (BRL21,252).  
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OBJECTIVES: Aclidinium bromide is a long-acting muscarinic antagonistic used 
in maintenance treatment of chronic obstructive pulmonary disease (COPD). We 
evaluated the cost-effectiveness of aclidinium 400μg twice daily as an alternative 
to tiotropium 18μg once daily for this indication in the US by conducting a 
model-based health economic study. METHODS: A cost-utility model was 
developed based on a time-in-state model structure. Patient characteristics in 
this model reflect those in aclidinium clinical studies: age >40 years; stable 
moderate-to-severe COPD; current or ex-smokers; post-salbutamol forced 
expiratory volume in 1 second (FEV1) ≥30% and <80% of predicted normal value 
and FEV1/forced vital capacity <70%. The model consists of 5 main health states 
indicating COPD severity and the level of utility, resource use, and costs. 
Treatment efficacy over 5-years time horizon was modeled using FEV1% 
predicted. Results of a network meta-analysis comparing aclidinium versus 
tiotropium were used to estimate disease progression during the first 24 weeks, 
while a common annual decline after 24 weeks was used, based on UPLIFT study 
data. Quality of life was assessed using utility scores in US patients from UPLIFT. 
Cost effectiveness was assessed as incremental cost per quality-adjusted life 
year (QALY) gained. The analysis was performed from a US third-party payer 
perspective. RESULTS: Over 5 years, 4.52 life years were accumulated for both 
aclidinium and tiotropium, with QALYs of 3.50 and 3.49, respectively, and 
marginally lower numbers of exacerbations for aclidinium. Aclidinium showed 
lower mean total health care costs vs tiotropium (US$126,274 vs US$128,591, 
respectively). In all scenario analyses performed, aclidinium was associated with 
lower costs and marginally greater QALYs vs tiotropium. Limitations include use 
of network meta-analysis to estimate treatment effect and extrapolation of trial 
results. CONCLUSIONS: These results indicate that aclidinium is potentially 
more cost-effective than tiotropium for the maintenance treatment of patients 
with moderate-to-severe COPD.  
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